Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Midostaurin in patients with Acute Myeloid Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.